CRRT.F Stock Overview
A dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Crescita Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.30 |
52 Week High | CA$0.55 |
52 Week Low | CA$0.056 |
Beta | 1.7 |
11 Month Change | -6.28% |
3 Month Change | -6.28% |
1 Year Change | -38.73% |
33 Year Change | -57.54% |
5 Year Change | -56.90% |
Change since IPO | -74.21% |
Recent News & Updates
Recent updates
Shareholder Returns
CRRT.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -1.2% | -0.06% |
1Y | -38.7% | 18.1% | 20.5% |
Return vs Industry: CRRT.F underperformed the US Pharmaceuticals industry which returned 18.1% over the past year.
Return vs Market: CRRT.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
CRRT.F volatility | |
---|---|
CRRT.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CRRT.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CRRT.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | n/a | Serge Verreault | www.crescitatherapeutics.com |
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations that can deliver actives into or through the skin.
Crescita Therapeutics Inc. Fundamentals Summary
CRRT.F fundamental statistics | |
---|---|
Market cap | US$7.50m |
Earnings (TTM) | -US$1.70m |
Revenue (TTM) | US$13.04m |
0.6x
P/S Ratio-4.4x
P/E RatioIs CRRT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRRT.F income statement (TTM) | |
---|---|
Revenue | CA$17.92m |
Cost of Revenue | CA$7.88m |
Gross Profit | CA$10.04m |
Other Expenses | CA$12.38m |
Earnings | -CA$2.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.12 |
Gross Margin | 56.03% |
Net Profit Margin | -13.06% |
Debt/Equity Ratio | 0% |
How did CRRT.F perform over the long term?
See historical performance and comparison